About Gradient Denervation Technologies
Gradient Denervation Technologies is a company based in Paris (France) founded in 2020. Gradient Denervation Technologies has raised $19.16 million across 3 funding rounds from investors including EIT Health, Asabys Partners and Thuja Capital. Gradient Denervation Technologies offers products and services including Pulmonary Artery Denervation System. Gradient Denervation Technologies operates in a competitive market with competitors including Pulmonx, Neurent Medical, Spiration, Uptake Medical and Emphasys Medical, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$19.16 M (USD)
in 3 rounds
-
Latest Funding Round
$15.02 M (USD), Series A
Sep 07, 2023
-
Investors
EIT Health
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gradient Denervation Technologies
Gradient Denervation Technologies offers a comprehensive portfolio of products and services, including Pulmonary Artery Denervation System.
Minimally-invasive catheter for treating pulmonary hypertension in heart failure patients.
People of Gradient Denervation Technologies
Unlock access to complete
Software Development Team
1 people
Leadership Team
1 people
COO Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of Gradient Denervation Technologies
Gradient Denervation Technologies has successfully raised a total of $19.16M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $15.02 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gradient Denervation Technologies
Gradient Denervation Technologies has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include EIT Health, Asabys Partners and Thuja Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US
|
Locked | Locked | Locked | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked |
Investor details for Gradient Denervation Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gradient Denervation Technologies
Investment portfolio details for Gradient Denervation Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gradient Denervation Technologies
Detailed financials for Gradient Denervation Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gradient Denervation Technologies Comparisons
Peer comparison for Gradient Denervation Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gradient Denervation Technologies
Gradient Denervation Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pulmonx, Neurent Medical, Spiration, Uptake Medical and Emphasys Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of smart devices for treating pulmonary diseases
|
|
| Locked | Locked | Locked |
Smart devices for minimally invasive rhinitis treatment are developed.
|
|
| Locked | Locked | Locked |
IntraBronchial Valve to treat lung disease
|
|
| Locked | Locked | Locked |
Targeted vapor therapy is developed for endoscopic lung volume reduction.
|
|
| Locked | Locked | Locked |
Endobronchial valves for emphysema treatment are developed.
|
Detailed competitors of Gradient Denervation Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gradient Denervation Technologies
Complete news archive for Gradient Denervation Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gradient Denervation Technologies
Gradient Denervation Technologies was founded in 2020.
Gradient Denervation Technologies is headquartered in Paris, France.
Martin Grasse is the current CEO of Gradient Denervation Technologies.
Gradient Denervation Technologies is a funded company, having raised a total of $19.16M across 3 funding rounds to date.
Gradient Denervation Technologies was founded in 2020 and is based in Paris, France. Operations focus on the medical device sector, where endovascular, catheter-based solutions are developed to address pulmonary hypertension. Therapy is offered to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics. The company is led by CEO Martin Grasse, with activities centered on innovative treatments for cardiovascular conditions.
Gradient Denervation Technologies's top competitors include Pulmonx, Neurent Medical and Spiration.
Gradient Denervation Technologies offers Pulmonary Artery Denervation System.
Gradient Denervation Technologies has 4 investors. Key investors include EIT Health, Asabys Partners, Thuja Capital, and Sofinnova Partners.